More than half of doctors are unaware of the so-called "Sunshine Act," a provision of health reform that's intended to expose financial relationships between drug and device manufacturers and certain health care providers, tech firm MMIS Inc. reported Monday. Even more say they are "deeply concerned" that the law will create a publicly accessible database of physician payment information.

The Centers for Medicare and Medicaid Services released the final rule for the Sunshine Act Feb. 1 after a long delay. This rule finalizes the provisions that require manufacturers of drugs, devices, biologicals, and medical supplies covered by Medicare, Medicaid or the Children's Health Insurance Program to report payments or other transfers of value they make to physicians and teaching hospitals to CMS. CMS will then post that data to a public website. The final rule also requires manufacturers and group purchasing organizations to disclose to CMS physician ownership or investment interests.

The survey revealed that of the more than 1,000 physicians questioned, more than half admitted they didn't know that the law requires pharmaceutical and medical device companies to report on expenditures annually, without physician review of the data to correct any inconsistencies or errors, prior to submission to the government.  The majority—63 percent—also said they "were deeply concerned" that a record of these payments will be available in a publicly searchable database.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.